SAMN03290943
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- COAGULATION+0.300
- HEDGEHOG_SIGNALING+0.300
- APICAL_SURFACE+0.200
- BILE_ACID_METABOLISM+0.200
- COMPLEMENT+0.200
- HYPOXIA+0.200
- KRAS_SIGNALING_DN+0.200
- KRAS_SIGNALING_UP+0.200
Top 10 suppressed
- DNA_REPAIR-0.400
- MYC_TARGETS_V1-0.400
- MYC_TARGETS_V2-0.400
- OXIDATIVE_PHOSPHORYLATION-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- E2F_TARGETS-0.200
- G2M_CHECKPOINT-0.200
- INTERFERON_ALPHA_RESPONSE-0.200
- NOTCH_SIGNALING-0.200
- P53_PATHWAY-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A3SL-01A-21R-A22U-07 | — | — | 0.857 |
| 2 | MNG313 | — | — | 0.849 |
| 3 | TCGA-BT-A20R-01A-12R-A16R-07 | — | — | 0.823 |
| 4 | TCGA-KQ-A41S-01A-12R-A33J-07 | — | — | 0.820 |
| 5 | MNG306 | — | — | 0.818 |
| 6 | MNG931 | — | — | 0.809 |
| 7 | TCGA-55-6981-01A-11R-1949-07 | — | cohortA1 | 0.809 |
| 8 | 34a7b3e9-caae-48d1-97a4-2bcb00fa2383 | — | — | 0.808 |
| 9 | SRR5088862 | — | — | 0.787 |
| 10 | MNG325 | — | — | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |